Amgen Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax of -$31.00 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax · last filed 2015-11-02
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-09-30 was -$31.00M, a 123.13% decline year-over-year.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-06-30 was -$67.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-03-31 was $104.00M, a 10300.00% increase year-over-year.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-12-31 was $58.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2014 was $178.00M, a 17700.00% increase from fiscal 2013.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2013 was $1.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2012 was -$41.00M, a 295.24% decline from fiscal 2011.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2011 was $21.00M, a 61.82% decline from fiscal 2010.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$31.00M 10-Q · filed 2015-11-02 | -$98.00M derived: sum of 2 quarters · filed 2015-11-02 | $6.00M derived: sum of 3 quarters · filed 2015-11-02 | $64.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-06-30 | -$67.00M 10-Q · filed 2015-11-02 | $37.00M derived: sum of 2 quarters · filed 2015-11-02 | $95.00M derived: sum of 3 quarters · filed 2015-11-02 | $229.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-03-31 | $104.00M 10-Q · filed 2015-11-02 | $162.00M derived: sum of 2 quarters · filed 2015-11-02 | $296.00M derived: sum of 3 quarters · filed 2015-11-02 | $281.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-12-31 | $58.00M derived: 10-K 12 month − 3 quarters · filed 2015-02-19 | $192.00M derived: sum of 2 quarters · filed 2015-02-19 | $177.00M derived: sum of 3 quarters · filed 2015-02-19 | $178.00M 10-K · filed 2015-02-19 |
| 2014-09-30 | $134.00M 10-Q · filed 2014-10-29 | $119.00M derived: sum of 2 quarters · filed 2014-10-29 | $120.00M derived: sum of 3 quarters · filed 2014-10-29 | |
| 2014-06-30 | -$15.00M 10-Q · filed 2014-10-29 | -$14.00M derived: sum of 2 quarters · filed 2014-10-29 | ||
| 2014-03-31 | $1.00M 10-Q · filed 2014-10-29 | |||
| 2013-12-31 | $1.00M 10-K · filed 2015-02-19 | |||
| 2013-09-30 | -$49.00M 10-Q · filed 2013-10-29 | -$36.00M derived: sum of 2 quarters · filed 2013-10-29 | $8.00M derived: sum of 3 quarters · filed 2013-10-29 | |
| 2013-06-30 | $13.00M 10-Q · filed 2013-10-29 | $57.00M derived: sum of 2 quarters · filed 2013-10-29 | ||
| 2013-03-31 | $44.00M 10-Q · filed 2013-10-29 | |||
| 2012-12-31 | -$41.00M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | $21.00M 10-K · filed 2014-02-24 | |||
| 2010-12-31 | $55.00M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |